A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 3, 2009, Pages 455-462

  Leary, Alexandra ^a   Assersohn, L ^a   Cunningham, D ^a   Norman, A R ^a   Chong, G ^a   Brown, G ^a   Ross, P J ^a   Costello, C ^a   Higgins, L ^a   Oates, J ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Capecitabine; Gastro oesophageal cancer; Irinotecan; Second line chemotherapy

Indexed keywords

ATROPINE; CA 19-9 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CIPROFLOXACIN; IRINOTECAN; LOPERAMIDE; RALTITREXED;

ADULT; AGED; ALOPECIA; ANEMIA; ANTICHOLINERGIC SYNDROME; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HUMAN; KAPLAN MEIER METHOD; LETHARGY; LUNG EMBOLISM; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; STOMACH CANCER; STOMACH CARCINOMA; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; STOMACH NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 67349126229     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0893-5     Document Type: Article

References (33)

1. International Agency for Research on Cancer (2003) World Cancer Report
2. A Webb D Cunningham JH Scarffe P Harper A Norman JK Joffe 1997 Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer J Clin Oncol 15 1 261 267 (Pubitemid 27020582)
3. P Ross M Nicolson D Cunningham J Valle M Seymour P Harper 2002 Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer J Clin Oncol 20 8 1996 2004 (Pubitemid 34413593)
4. PC Thuss-Patience A Kretzschmar M Repp D Kingreen D Hennesser S Micheel 2005 Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study J Clin Oncol 23 3 494 501 (Pubitemid 46237444)
5. D Cunningham WH Allum SP Stenning JN Thompson CJ Van de Velde M Nicolson 2006 Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 1 11 20
6. JS Macdonald SR Smalley J Benedetti SA Hundahl NC Estes GN Stemmermann 2001 Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 10 725 730 (Pubitemid 34936653)
7. K Futatsuki A Wakui I Nakao Y Sakata M Kambe Y Shimada 1994 Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group Gan To Kagaku Ryoho 21 7 1033 1038
8. LB Saltz JY Douillard N Pirotta M Alakl G Gruia L Awad 2001 Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard Oncologist 6 1 81 91 (Pubitemid 32155818)
9. LB Saltz JV Cox C Blanke LS Rosen L Fehrenbacher MJ Moore 2000 Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 13 905 914 (Pubitemid 30727802)
10. CD Blanke DG Haller AB Benson ML Rothenberg J Berlin M Mori 2001 A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma Ann Oncol 12 11 1575 1580 (Pubitemid 34065887)
11. C Pozzo C Barone J Szanto E Padi C Peschel J Bukki 2004 Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study Ann Oncol 15 12 1773 1781 (Pubitemid 40017161)
12. L Assersohn G Brown D Cunningham C Ward J Oates JS Waters 2004 Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma Ann Oncol 15 1 64 69 (Pubitemid 38145530)
13. A de Gramont JF Bosset C Milan P Rougier O Bouche PL Etienne 1997 Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study J Clin Oncol 15 2 808 815 (Pubitemid 27074252)
14. DW Rea JW Nortier WW Ten Bokkel Huinink S Falk DJ Richel T Maughan 2005 A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer Ann Oncol 16 7 1123 1132 (Pubitemid 41418315)
15. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 205 216
16. Hecht JR, Blanke CD, Benson III AB, Lenz HJ (2003) Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia. Oncology (Williston Park) 17(9 Suppl 8):13-15
17. HJ Kang HM Chang TW Kim MH Ryu HJ Sohn JH Yook 2005 Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy Br J Cancer 92 2 246 251 (Pubitemid 40347314)
18. ST Kim WK Kang JH Kang KW Park J Lee SH Lee 2005 Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer Br J Cancer 92 10 1850 1854 (Pubitemid 40826132)
19. J Schuller J Cassidy E Dumont B Roos S Durston L Banken 2000 Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Cancer Chemother Pharmacol 45 4 291 297 (Pubitemid 30151522)
20. PM Hoff R Ansari G Batist J Cox W Kocha M Kuperminc 2001 Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study J Clin Oncol 19 8 2282 2292 (Pubitemid 32366981)
21. JP Delord JY Pierga V Dieras F Bertheault-Cvitkovic FL Turpin F Lokiec 2005 A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours Br J Cancer 92 5 820 826 (Pubitemid 40462624)
22. JH Baek JG Kim SB Jeon YS Chae DH Kim SK Sohn 2006 Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer Br J Cancer 94 10 1407 1411 (Pubitemid 43772274)
23. S Hironaka S Zenda N Boku A Fukutomi T Yoshino Y Onozawa 2006 Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer Gastric Cancer 9 1 14 18
24. JA Ajani J Baker PW Pisters L Ho PF Mansfield BW Feig 2002 Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma Oncology (Williston Park) 16 5 Suppl 5 16 18
25. F Giuliani S Molica E Maiello C Battaglia V Gebbia M Di Bisceglie 2005 Irinotecan (CPT-11) and mitomycin-C(MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106) Am J Clin Oncol 28 6 581 585 (Pubitemid 41790010)
26. M Stahl C Muller W Koster H Wilke 2005 Second-line chemotherapy of advanced disseminated gastric cancer after cisplatin, infusional 5-fluorouracil, folinic acid (PLF): benefit dependent on progression-free interval after first-line therapy Onkologie 28 10 499 502 (Pubitemid 41420846)
27. MM Borner J Bernhard D Dietrich R Popescu M Wernli P Saletti 2005 A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity Ann Oncol 16 2 282 288 (Pubitemid 40309311)
28. M Koopman NF Antonini J Douma J Wals AH Honkoop FL Erdkamp 2007 Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial Lancet 370 9582 135 142 (Pubitemid 47042893)
29. CH Köhne J De Greve JT Hartmann I Lang P Vergauwe K Becker 2007 Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015 Ann Oncol 19 5 920 926
30. CS Fuchs J Marshall E Mitchell R Wierzbicki V Ganju M Jeffery 2007 Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study J Clin Oncol 25 30 4779 4786 (Pubitemid 350086481)
31. Schmiegel WH, Reinacher-Schick A, Freier W et al (2007) Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin versus capecitabine/irinotecan in advanced CRC: a randomized phase II study of the AIO GI tumor study group. Proc Am Soc Clin Oncol 25:(abstract 4034)
32. ME Burge D Smith C Topham DP Jackson DA Anthoney F Halstead 2006 A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma Br J Cancer 94 9 1281 1286
33. SC Oh HY Sur HJ Sung IK Choi SS Park JH Seo 2007 A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer Br J Cancer 96 10 1514 1519 (Pubitemid 46762953)